Search Result

Results for "

Direct Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) AAK1 (1) Acetyl-CoA Carboxylase (1) ADC Antibody (1) ADC Payload (1) Adenosine Deaminase (2) Adenosine Receptor (1) Adrenergic Receptor (2) Akt (3) Aldehyde Dehydrogenase (ALDH) (4) Aldose Reductase (1) AMPK (2) Amylases (1) Amyloid-β (5) Androgen Receptor (1) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (3) AP-1 (3) Apoptosis (28) Arf Family GTPase (1) Aryl Hydrocarbon Receptor (1) Atg8/LC3 (1) ATM/ATR (1) Aurora Kinase (1) Autophagy (10) Bacterial (14) BCRP (4) Beta-lactamase (2) Beta-secretase (1) Calcium Channel (6) Calmodulin (1) Carboxypeptidase (1) Casein Kinase (1) Caspase (2) CCR (4) CD2 (1) CD38 (2) CD73 (1) CDK (2) Cholinesterase (ChE) (11) CMV (4) Complement System (1) COX (7) CXCR (1) Cytochrome P450 (4) DAPK (1) Dengue Virus (1) Deubiquitinase (4) Dihydroorotate Dehydrogenase (2) DNA Methyltransferase (2) DNA/RNA Synthesis (17) Dopamine Transporter (4) Drug Intermediate (1) Drug Metabolite (2) Drug-Linker Conjugates for ADC (1) DYRK (1) E1/E2/E3 Enzyme (1) EAAT (1) EGFR (2) Endogenous Metabolite (7) Epigenetic Reader Domain (2) ERK (4) Factor VIIa (1) Factor Xa (17) FAK (1) Fatty Acid Synthase (FASN) (2) Ferroportin (1) FGFR (1) Filovirus (2) FLAP (2) Fungal (3) Glutathione Peroxidase (1) Glutathione S-transferase (1) HBV (2) HCV (1) HCV Protease (2) HDAC (2) Herbicide (1) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (3) Histone Methyltransferase (3) HIV (5) HSP (1) HSV (3) iGluR (1) IKK (3) Influenza Virus (2) Interleukin Related (10) IPK Superfamily (1) Isotope-Labeled Compounds (17) JNK (2) Keap1-Nrf2 (2) Kinesin (1) Leukotriene Receptor (3) Ligands for Target Protein for PROTAC (1) Lipase (1) Lipoxygenase (6) LXR (2) MDM-2/p53 (1) Microtubule/Tubulin (3) MMP (5) Monoamine Oxidase (4) mTOR (4) Myosin (1) Na+/K+ ATPase (1) NADPH Oxidase (4) NF-κB (10) NO Synthase (2) NOD-like Receptor (NLR) (6) OAT (1) Opioid Receptor (2) P-glycoprotein (2) P2Y Receptor (3) p38 MAPK (8) Parasite (12) PARP (1) PD-1/PD-L1 (1) PDGFR (1) PDK-1 (2) PERK (2) PGE synthase (1) Phosphatase (3) Phosphodiesterase (PDE) (6) Phospholipase (4) Phytohormone (3) PI3K (4) Pim (1) PKA (2) PKC (4) Potassium Channel (8) PPAR (3) Prolyl Endopeptidase (PREP) (1) Prostaglandin Receptor (1) RABV (1) Ras (2) Reactive Oxygen Species (ROS) (8) Reference Standards (40) Renin (3) Reverse Transcriptase (1) RIP kinase (2) RSV (2) SARS-CoV (7) Serotonin Transporter (1) Sirtuin (1) Small Interfering RNA (siRNA) (2) Sodium Channel (3) Src (1) Tau Protein (2) TGF-beta/Smad (6) TGF-β Receptor (2) Thrombin (42) TNF Receptor (5) Toll-like Receptor (TLR) (5) Topoisomerase (5) Transmembrane Glycoprotein (1) TROP2 (1) VDAC (1) VEGFR (6) Wnt (1) α-synuclein (1) γ-secretase (1)
By Research Areas:	Cancer (106) Cardiovascular Disease (86) Endocrinology (9) Infection (45) Inflammation/Immunology (54) Metabolic Disease (29) Neurological Disease (55)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

278

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164789

Sacituzumab tirumotecan SKB264; MK-2870	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab tirumotecan is an antibody-drug conjugate and *TROP2*-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC₅₀ of 2.787 ng/ml, TROP2 K_a of 0.3083 nM, and topoisomerase I IC₅₀ of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .

HY-B0375

Argatroban 5 Publications Verification MD-805; MCI-9038	Thrombin	Cardiovascular Disease Cancer
Argatroban (MD-805) is a direct, selective thrombin inhibitor.

HY-10274

Dabigatran etexilate 4 Publications Verification BIBR 1048	Thrombin	Cardiovascular Disease
Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-50903

Rivaroxaban 15+ Cited Publications BAY 59-7939	Factor Xa	Cardiovascular Disease Cancer
Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-10163

Dabigatran 5+ Cited Publications BIBR 953; BIBR 953ZW	Thrombin	Cardiovascular Disease Cancer
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (K_i=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-102084

LMT-28 10+ Cited Publications	Interleukin Related	Inflammation/Immunology
LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130 .

HY-11005

BX-912 5+ Cited Publications	PDK-1 Apoptosis	Cancer
BX-912 is a direct, selective, and ATP-competitive PDK1 inhibitor (IC₅₀=26 nM). BX-912 blocks PDK1/Akt signaling in tumor cells and inhibits the anchorage-dependent growth of a variety of tumor cell lines in culture or induces apoptosis .

HY-103334

MAFP 5 Publications Verification Methyl Arachidonyl Fluorophosphonate	Phospholipase	Cardiovascular Disease Neurological Disease Metabolic Disease
MAFP (Methyl Arachidonyl Fluorophosphonate) is an selective, active-site directed and irreversible inhibitor of cPLA2 and iPLA2. MAFP is also a potent irreversible inhibitor of anandamide amidase.

HY-103666

CY-09 Maximum Cited Publications 50 Publications Verification	NOD-like Receptor (NLR)	Inflammation/Immunology
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .

HY-B1099

Hycanthone 2 Publications Verification	DNA/RNA Synthesis Topoisomerase Parasite	Infection
Hycanthone is a thioxanthenone DNA intercalator and inhibits RNA synthesis as well as the DNA topoisomerases I and II. Hycanthone inhibits nucleic acid biosynthesis and inhibits apurinic endonuclease-1 (APE1) by direct protein binding with a K_D of 10 nM. Hycanthone is a bioactive metabolite of Lucanthone (HY-B2098) and has anti-schistosomal agent .

HY-15724

Vercirnon 3 Publications Verification GSK-1605786; CCX282-B; Traficet-EN	CCR Ligands for Target Protein for PROTAC	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-D0939

Direct Blue 1 2 Publications Verification Chicago Sky Blue 6B	Amyloid-β NF-κB	Inflammation/Immunology
Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity .

HY-171689

Puxitatug samrotecan AZD 8205; P-Sam	Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
Puxitatug samrotecan (AZD 8205) is a *B7-H4*-directed antibody-drug conjugate (ADC) bearing a Topoisomerase I inhibitor (TOP1i) payload. Puxitatug samrotecan improves HR ⁺/HER2 ^- breast cancer .

HY-119711

NNGH	MMP	Cancer
NNGH is a stromelysin-1 (MMP-3) inhibitor. MMP-3 is both a direct transcriptional target and a necessary contributor of the Wnt/β-catenin signaling pathway. Matrix metalloproteinases (MMPs) play a well-defined role in later stages of tumor progression .

HY-N6961

Lapachol 3 Publications Verification	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite	Infection Inflammation/Immunology Cancer
Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .

HY-B0375A

Argatroban monohydrate 5 Publications Verification MD-805 monohydrate; MCI-9038 monohydrate	Thrombin	Cardiovascular Disease Infection Cancer
Argatroban (monohydrate) (MD-805 (monohydrate)) is a direct, selective thrombin inhibitor.

HY-10274A

Dabigatran etexilate mesylate 4 Publications Verification BIBR 1048MS; Dabigatran etexilate methanesulfonate	Thrombin	Cardiovascular Disease
Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-50903S

Rivaroxaban-d4 1 Publications Verification BAY 59-7939-d₄	Factor Xa	Cardiovascular Disease
Rivaroxaban-d₄ (BAY 59-7939-d₄) is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-103643

Fumagillol (-)-Fumagillol	Bacterial	Infection
Fumagillol is a direct precursor of fumagillin. Fumagillin, as an antimicrobial agent, is a potent and selective inhibitor of angiogenesis .

HY-167851

CCX662	CXCR	Neurological Disease Cancer
CCX662 is a selective CXCR7 inhibitor with human IC₅₀ values of 9 nM (buffer) and 18 nM (100% human serum), and rat IC₅₀ of 14 nM (100% rat serum). CCX662 blocks CXCL12 binding to CXCR7, inhibits *CXCR4*-directed trans-endothelial migration of CXCR4 ⁺/CXCR7 ⁺ cells. CCX662 can be used for the research of glioblastoma multiforme .

HY-U00422

K-756 2 Publications Verification	PARP	Cancer
K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of TNKS1 and TNKS2 with IC₅₀s of 31 and 36 nM, respectively.

HY-125989

2-Methylthio-AMP 1 Publications Verification 2-MeSAMP; 2-Methylthioadenosine 5′-monophosphate; 2-Methylthioadenosine 5′-phosphate	P2Y Receptor	Cardiovascular Disease
2-Methylthio-AMP (2-MeSAMP) is a selective and direct P2Y₁₂ antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation .

HY-126302

DMT1 blocker 2 3 Publications Verification	Ferroportin	Metabolic Disease
DMT1 blocker 2 is a direct inhibitor of divalent metal transporter 1 (DMT1), with an IC₅₀ of 0.83 μM. DMT1 blocker 2 can block iron uptake by enterocytes in vivo .

HY-151931

JA-ACC Jasmonyl-ACC	Phytohormone	Metabolic Disease
JA-ACC (Jasmonyl-ACC) is a derivative of 1-aminocyclopropane-1-carboxylic acid (ACC). ACC is the direct precursor of the plant hormone ethylene. JA-ACC inhibits root growth in Arabidopsis and the inhibition is independent of jasmonic acid (JA) signaling .

HY-19628

OD36	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36 is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with K_Ds of 37 nM .

HY-141487

CLP-3094 2 Publications Verification	Androgen Receptor	Metabolic Disease Inflammation/Immunology
CLP-3094 is a potent BF3 (binding function 3)-directed inhibitor of the androgen receptor (AR). CLP-3094 inhibits AR transcriptional activity (IC₅₀=4 μM) . CLP-3094 is a selective, potent GPR142 antagonist .

HY-112373

Aurora kinase inhibitor-3	Aurora Kinase	Others
Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC₅₀ of 42 nM, and weakly inhibits EGFR with an IC₅₀ of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .

HY-156395

MN551	E1/E2/E3 Enzyme	Cancer
MN551 is a potent inhibitor of cysteine-directed electrophilic covalent that plays important roles in the biology of SOCS2 and its CRL5 complex, and as E3 ligase handles in proteolysis targeting chimera (PROTACs) to induce targeted protein degradation .

HY-136450

Triclabendazole sulfoxide TCBZ-SO	Parasite BCRP	Infection Cancer
Triclabendazole sulfoxide (TCBZ-SO) is an orally active ABCG2 inhibitor with antiparasitic activity. Triclabendazole sulfoxide inhibits ABCG2-mediated active efflux and ATPase activity. Triclabendazole sulfoxide increases the intracellular accumulation of Mitoxantrone (HY-13502). Triclabendazole sulfoxide reduces the apical-directed transepithelial transport of Nitrofurantoin and Danofloxacin, while increasing their basolateral-directed transepithelial transport. Triclabendazole sulfoxide elevates the plasma levels of sulfasalazine in wild-type mice. Triclabendazole sulfoxide decreases ABCG2-mediated secretion of Nitrofurantoin into milk in wild-type lactating mice. Triclabendazole sulfoxide can be used in the research of insecticidal agents and cancers such as breast cancer .

HY-103180

2'-MeCCPA 2-Chloro-N-cyclopentyl-2′-C-methyladenosine	Adenosine Receptor	Neurological Disease
2'-MeCCPA is a potent and selective A1 adenosine receptors (A1AR) agonist. 2'-MeCCPA efficiently inhibits cAMP modulation in both direct pathway medium spiny neurons (dMSNs) and indirect pathway medium spiny neurons (iMSNs) .

HY-P10108

Hexokinase II VDAC binding domain peptide, cell-permeable Hxk2VBD peptide, cell-permeable	Hexokinase	Neurological Disease
Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .

HY-10515

BX-320	PDK-1	Cancer
BX-320 is a selective, ATP-competitive, orally acitive, and direct PDK1 inhibitor with an IC₅₀ of 30 nM in a direct kinase assay format. BX-320 also induces apoptosis. Anticancer effect .

HY-10217

Thrombin Inhibitor 2	Thrombin	Cardiovascular Disease
Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor, extracted from US8541580B2. Thrombin Inhibitor 2 has antithrombotic activity .

HY-102076

0990CL	Adrenergic Receptor	Others
0990CL is a specific heterotrimeric Gαi subunit inhibitor by direct interaction with Gαi. 0990CL is able to block α2AR mediated regulation of cAMP .

HY-W015664

2-Methylheptanoic acid	Fungal	Infection
2-Methylheptanoic acid is a naturally occurring branched-chain medium-chain fatty acid with fumigant activity against Aspergillus flavus. 2-Methylheptanoic acid inhibits the growth of Aspergillus flavus and kills its spores via two modes of action, namely fumigation and direct contact, with its fumigant activity being stronger than its direct contact activity. 2-Methylheptanoic acid can be used in studies related to Aspergillus flavus infection .

HY-76948

5-R-Rivaroxaban 1 Publications Verification	Factor Xa	Cardiovascular Disease
5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM).

HY-10163S

Dabigatran-d4 BIBR 953-d₄; BIBR 953ZW-d₄	Isotope-Labeled Compounds Thrombin	Cardiovascular Disease
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-15724A

Vercirnon sodium 3 Publications Verification GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium	CCR	Inflammation/Immunology Endocrinology
Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca ²⁺ mobilization and chemotaxis on Molt-4 cells with IC₅₀ values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC₅₀s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC₅₀ values of 2.8 and 2.6 nM, respectively .

HY-50903R

Rivaroxaban (Standard) BAY 59-7939 (Standard)	Reference Standards Factor Xa	Cardiovascular Disease Cancer
Rivaroxaban (Standard) is the analytical standard of Rivaroxaban. This product is intended for research and analytical applications. Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-110019

Indatraline hydrochloride Lu 19-005	Serotonin Transporter Dopamine Transporter	Neurological Disease
Indatraline hydrochloride (Lu 19-005) is a non-selective monoamine transporter inhibitor that blocks the reuptake of neurotransmitters (dopamine, serotonin, and norepinephrine). Indatraline hydrochloride can be used for the research of antidepressive. Indatraline hydrochloride induces autophagy while simultaneously inhibiting cell proliferation. Indatraline hydrochloride may also serve to direct the development of new agents for autophagy-related diseases such as atherosclerosis or restenosis .

HY-18660

Ciraparantag PER977	Factor Xa Thrombin	Cardiovascular Disease
Ciraparantag (PER977) is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .

HY-108739

Idarucizumab BI 655075	Thrombin	Cardiovascular Disease
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .

HY-D1270

Direct Violet 1	SARS-CoV	Infection
Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2 inhibitor with IC₅₀s of 1.47-2.63 μM .

HY-114511

BMS-593214	Factor VIIa	Cardiovascular Disease
BMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT) .

HY-153493A

PF-04523655 sodium	Small Interfering RNA (siRNA)	Metabolic Disease
PF-04523655 sodium is a siRNA directed against RTP801 gene. RTP801 sodium is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.

HY-139031

ALDH1A2-IN-1	Aldehyde Dehydrogenase (ALDH)	Endocrinology
ALDH1A2-IN-1 is an active site-directed reversible ALDH1A2 inhibitor (IC₅₀=0.91 μM; Kd=0.26 μM) with several hydrophobic interactions .

HY-10163S1

Dabigatran-d3 BIBR 953-d₃; BIBR 953ZW-d₃	Thrombin	Cardiovascular Disease
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163R

Dabigatran (Standard) BIBR 953 (Standard); BIBR 953ZW (Standard)	Reference Standards Thrombin	Cardiovascular Disease Cancer
Dabigatran (Standard) is the analytical standard of Dabigatran. This product is intended for research and analytical applications. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM) .

HY-129944

MJ33-OH	Phospholipase	Inflammation/Immunology
MJ33-OH is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 .

HY-19628A

OD36 hydrochloride	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36hydrochloride is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with K_Ds of 37 nM .

Cat. No.	Product Name

HY-L244

High-Efficiency Gene Editing Compound Library

743 compounds

In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies.

To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 743 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

HY-L145

Antihypertensive Compound Library

900 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 900 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

HY-L132

Chemokine Compound Library

242 compounds

Chemokines, or chemotactic cytokines, are small cytokines or signaling proteins secreted by cells. They are a component of intercellular communication, controlling the directional movement of immune cells especially leukocytes, as well as other cell types, for instance, endothelial and epithelial cells, which are essential to maintain human health and the function of the immune system.

The biological effects of chemokines are achieved by binding to chemokine receptors, which are G protein-coupled receptors found on the surface of leukocytes. Some chemokine receptors are involved in directing tumor metastasis and over-expression by certain tumors. So inhibiting the interaction between chemokine and chemokine receptors on the surface of tumor cells may be a new possible therapeutic approach. Some chemokine receptors are coreceptors for HIV entry, and related inhibitors have been approved by the FDA to treat patients with HIV. Obviously, chemokines and chemokine receptors have become new targets for studying cancer, HIV, inflammation, and other diseases.

MCE supplies a unique collection of 242 chemokine or chemokine receptor inhibitors and activators, all of which have the identified inhibitory or activated effect on chemokine or chemokine receptors. MCE Chemokine Library is a useful tool for drug research related to cancer, AIDS, and wound therapy.

HY-L165

Dopamine Receptor Compound Library

271 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 271 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

HY-L073

Anti-Hepatitis C Virus Compound Library

392 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 392 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Type

HY-164789

Sacituzumab tirumotecan

SKB264; MK-2870

Fluorescent Dyes

Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC₅₀ of 2.787 ng/ml, TROP2 K_a of 0.3083 nM, and topoisomerase I IC₅₀ of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .

HY-P3371

Ifinatamab deruxtecan

DS-7300a; MABX-9001a; I-DXd

Fluorescent Dyes

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-D0939

Direct Blue 1 2 Publications Verification Chicago Sky Blue 6B	Fluorescent Dyes
Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity .

HY-D1270

Direct Violet 1	Fluorescent Dyes
Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2 inhibitor with IC₅₀s of 1.47-2.63 μM .

Cat. No.	Product Name	Type

HY-B1102

Evans Blue

25+ Cited Publications

Direct Blue 53; T-1824; C.I. 23860

Biochemical Assay Reagents

Evans Blue (Direct Blue 53) is a potent inhibitor of L-glutamate uptake via the membrane bound excitatory amino acid transporter (EAAT). Evans Blue is a L-glutamate and kainate receptor-mediated currents inhibitor. Evans Blue has a strong affinity towards serum albumin, making it a high molecular weight protein tracer. Evans Blue is also used to study BBB (blood-brain barrier) permeability .

HY-W016473

Adamantane-carboxylic acid

Biochemical Assay Reagents

Adamantane-carboxylic acid is a compound with inhibitory activity against microorganisms. Although its specific target has not been clearly defined, it can inhibit Gram-positive bacteria and some Gram-negative bacteria. It forms a 1-monoacylglycerol derivative through a direct reaction with glycidol, and exerts its antibacterial effect by mechanisms such as altering the permeability of the bacterial cell membrane. This compound can be used in the research of antibacterial agents in the food and cosmetic industries to reduce harmful microbial flora and extend the shelf life of products .

HY-Y0070

Cyanamide

Biochemical Assay Reagents

Cyanamide is a cell division and plant growth inhibitor, as well as an allelochemical derived from Vicia villosa. Cyanamide inhibits root growth and biomass accumulation in a dose-dependent manner by disrupting the formation of mitotic spindles and phragmoplast complexes, reducing the number of mitotic cells and blocking the cell cycle. The effects of Cyanamide are partially reversible after removal from low-concentration environments. Cyanamide is also a specific inhibitor of aldehyde dehydrogenase (ALDH). Although Cyanamide has no direct effect on tumor growth, it can significantly enhance the anti-tumor efficacy of Cyclophosphamide (HY-17420) at non-toxic doses by inhibiting the inactivation of Cyclophosphamide. Cyanamide enables Cyclophosphamide to exert equivalent therapeutic effects at lower doses, effectively inhibiting the growth of primary and metastatic tumors and prolonging the lifespan of tumor-bearing mice. Cyanamide is commonly used in studies related to ha-1 hepatoma and rls lymphosarcoma .

Cat. No.	Product Name	Target	Research Area

HY-P1929

Bivalirudin 5+ Cited Publications	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .

HY-P2310

Defensin HNP-1 human	Bacterial Parasite Apoptosis HIV HSV CMV TNF Receptor NOD-like Receptor (NLR) DNA/RNA Synthesis Influenza Virus	Cardiovascular Disease Infection
Defensin HNP-1 human is a type of human neutrophil peptide (HNPs). Defensin HNP-1 human possesses immunomodulatory functions and can delay the apoptosis of neutrophils. Defensin HNP-1 human inhibits DNA/RNA/protein synthesis and interferes with metabolic pathways, thus exhibiting broad antibacterial activity. Defensin HNP-1 human has direct inactivation effects on HIV, HSV-1, HSV-2, CMV, influenza virus, etc. Defensin HNP-1 human has antileishmanial activity. Defensin HNP-1 human is involved in endothelial cell dysfunction during the early development of atherosclerosis .

HY-P10735

GIP (mouse) Gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)	Lipase Apoptosis	Metabolic Disease
GIP (Gastric inhibitory polypeptide) (mouse) is a gastrointestinal hormone that is secreted by the intestinal K cells, and also expressed in and secreted from pancreatic islets. GIP (mouse) promotes insulin secretion from pancreatic β cells via the G-protein-coupled GIP receptor (GIPR). GIP (mouse) promotes pancreatic β cell proliferation and inhibits apoptosis. GIP (mouse) also exerts direct lipogenic effects on adipose tissue .

HY-P0131A

Laminin peptide CDPGYIGSR TFA Laminin (925-933) TFA	Peptides	Cancer
Laminin peptide CDPGYIGSR (Laminin (925-933)) TFA is a 67 kDa laminin receptor ligand and selective cell adhesion inducer. Laminin peptide CDPGYIGSR TFA not only promotes cell adhesion and mediates directed neurite outgrowth via matrix coating or covalent immobilization, but also inhibits neural crest cell migration under specific conditions. Laminin peptide CDPGYIGSR TFA inhibits lung colonization of melanoma cells, and suppresses the growth of Sarcoma 180 solid tumors and Lewis lung carcinoma (3LL) in mice. Laminin peptide CDPGYIGSR TFA also exerts significant anti-angiogenic effects by inhibiting embryonic angiogenesis in the chick chorioallantoic membrane and vascular endothelial cell migration induced by tumor-conditioned medium. Laminin peptide CDPGYIGSR TFA can be widely used in studies related to melanoma, Sarcoma 180, Lewis lung carcinoma (3LL), and other relevant areas .

HY-106228

HLF1-11	Fungal Bacterial Glutathione Peroxidase	Infection
HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses .

HY-15664

Bivalirudin TFA 5+ Cited Publications	Thrombin Interleukin Related RSV	Infection Cardiovascular Disease Inflammation/Immunology
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .

HY-P2310A

Defensin HNP-1 human TFA	Bacterial Parasite Apoptosis HIV HSV CMV TNF Receptor Interleukin Related NOD-like Receptor (NLR) DNA/RNA Synthesis Influenza Virus	Cardiovascular Disease Infection
Defensin HNP-1 human TFA is a type of human neutrophil peptide (HNPs). Defensin HNP-1 human TFA possesses immunomodulatory functions and can delay the apoptosis of neutrophils. Defensin HNP-1 human TFA inhibits DNA/RNA/protein synthesis and interferes with metabolic pathways, thus exhibiting broad antibacterial activity. Defensin HNP-1 human TFA has direct inactivation effects on HIV, HSV-1, HSV-2, CMV, influenza virus, etc. Defensin HNP-1 human TFA has antileishmanial activity. Defensin HNP-1 human TFA is involved in endothelial cell dysfunction during the early development of atherosclerosis .

HY-P10861A

RI-AG03 acetate	Tau Protein	Neurological Disease
RI-AG03 acetate is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 acetate inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 acetate mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 acetate suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 acetate can be used for research on tau-related diseases such as Alzheimer's disease .

HY-P10108

Hexokinase II VDAC binding domain peptide, cell-permeable Hxk2VBD peptide, cell-permeable	Hexokinase	Neurological Disease
Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .

HY-P10861

RI-AG03	Tau Protein	Neurological Disease
RI-AG03 is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 can be used for research on tau-related diseases such as Alzheimer's disease .

HY-P10404

PDpep1.3	α-synuclein	Others Neurological Disease
PDpep1.3 is a peptide inhibitor of α-synuclein that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .

HY-P11467

Gy-CATH	Bacterial p38 MAPK NF-κB PERK JNK	Cardiovascular Disease Infection
Gy-CATH is an anionic antimicrobial peptide. Gy-CATH activates MAPK and NF-κB signaling pathways (elevated levels of phospho-ERK, -p38, -JNK, -p65, and -IκBα). Gy-CATH upregulates the expression levels of three physiological anticoagulant pathways. Gy-CATH inhibits ADP-, Collagen-, and PMA-induced platelet aggregation. Gy-CATH has no direct antimicrobial activity, but shows significant preventive abilities against mice infected with Staphylococcus aureus, Escherichia coli, and Methicillin (HY-121544)-resistant Staphylococcus aureus. Gy-CATH exhibits potent immunomodulatory activity, enhancing macrophage-and neutrophil-mediated bactericidal functions. Gy-CATH significantly reduces the extent of pulmonary fibrin deposition and prevents thrombosis in mice .

Cat. No.	Product Name	Target	Research Area	Image

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-P99205

Glembatumumab	ADC Antibody	Cancer
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .

HY-P9976

Isatuximab 1 Publications Verification ch38SB19; hu38SB19; SAR-650984	CD38 Apoptosis	Cancer
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P99364

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

HY-P9974

Vantictumab 1 Publications Verification OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P99008

Atibuclimab 2 Publications Verification IC14	Toll-like Receptor (TLR)	Infection Neurological Disease Inflammation/Immunology
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38 Apoptosis	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody that targets the transmembrane receptor and extracellular enzyme CD38, a protein highly expressed in hematological malignancies, including multiple myeloma. Isatuximab (anti-CD38) exhibits anti-tumor activity through multiple biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell phagocytosis, and non-crosslinking direct induction of apoptosis. Isatuximab (anti-CD38) also directly inhibits the extracellular enzyme activity of CD38, which is related to many cellular functions .

HY-P990961

Palverafusp alfa IMM-2510; SYN-2510	VEGFR PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Palverafusp alfa (IMM-2510; SYN-2510) is a PD-L1/VEGF-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer .

HY-108739

Idarucizumab BI 655075	Thrombin	Cardiovascular Disease
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .

HY-P99516

Vulinacimab HLX-06	VEGFR	Cancer
Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer .

HY-P991543

BTI-322	CD2	Inflammation/Immunology Cancer
BTI-322 is a human IgG1κ antibody directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .

HY-P99886

Pexelizumab h5G1. 1-SC	Complement System Apoptosis	Cardiovascular Disease Neurological Disease
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0292

Oleuropein 5+ Cited Publications	Cardiovascular Disease Classification of Application Fields Anti-aging Plants Burseraceae Iridoids Canarium album (Lour.) Rauesch. Terpenoids Phenols Polyphenols Inflammation/Immunology Disease Research Fields Source Classification Cancer	Cytochrome P450 PPAR Apoptosis
Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .

HY-18980

Rottlerin Maximum Cited Publications 22 Publications Verification Mallotoxin; NSC 56346; NSC 94525	Structural Classification Chalcones Flavonoids Classification of Application Fields Phenols Polyphenols Euphorbiaceae Plants Disease Research Fields Mallotus philippensis Source Classification Cancer	PKC Autophagy Apoptosis HIV RABV
Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific PKC inhibitor, with IC₅₀ values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM. Rottlerin acts as a direct mitochondrial uncoupler, and stimulates autophagy by targeting a signaling cascade upstream of mTORC1. Rottlerin induces apoptosis via caspase 3 activation . Rottlerin inhibits HIV-1 integration and Rabies virus (RABV) infection .

HY-13295

Vinpocetine 5+ Cited Publications Ethyl apovincaminate	Cardiovascular Disease Neurological Disease Classification of Application Fields Anti-aging Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Apocynaceae Alkaloids Piperidine Alkaloids Disease Research Fields Source Classification Cancer	Sodium Channel IKK Phosphodiesterase (PDE)
Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na ⁺ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .

HY-113224

Desmosterol 5 Publications Verification	Microorganisms Classification of Application Fields Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Endogenous Metabolite LXR Fatty Acid Synthase (FASN) Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)
Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism . Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases .

HY-N7368

Hibifolin	Flavonols Flavonoids other families Neurological Disease Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Adenosine Deaminase Bacterial Caspase
Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (K_i = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC₅₀ = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .

HY-N0493

Pectolinarigenin 2 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Flavones Campylotropis hirtella (Franch.) Schindl. Phenols Polyphenols Plants Compositae Inflammation/Immunology Disease Research Fields Source Classification	COX Lipoxygenase NF-κB p38 MAPK ERK HIF/HIF Prolyl-Hydroxylase Keap1-Nrf2 PI3K Apoptosis Autophagy
Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G₂/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma .

HY-N6961

Lapachol 3 Publications Verification	Infection Quinones Structural Classification Classification of Application Fields Tabebuia avellanedae Bignoniaceae Plants Naphthalene Quinones Inflammation/Immunology Disease Research Fields	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite
Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .

HY-N5072

Desmethylglycitein 3 Publications Verification 4',6,7-Trihydroxyisoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Phenols Polyphenols Plants Disease Research Fields Isoflavones Source Classification Cancer	CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-N1942

5-O-Demethylnobiletin 3 Publications Verification 5-Demethylnobiletin	Flavonoids Neurological Disease Classification of Application Fields Flavones Rutaceae Plants Citrus Disease Research Fields Cancer	Lipoxygenase Leukotriene Receptor
5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Citrus jambhiri Lush., is a direct inhibition of 5-LOX (IC₅₀=0.1 μM), without affecting the expression of COX-2. 5-O-Demethylnobiletin (5-Demethylnobiletin) has anti-inflammatory activity, inhibits leukotriene B (4)(LTB₄) formation in rat neutrophils and elastase release in human neutrophils with an IC₅₀ of 0.35 μM .

HY-103643

Fumagillol (-)-Fumagillol	Infection Natural Products Microorganisms Disease Research Fields Source Classification	Bacterial
Fumagillol is a direct precursor of fumagillin. Fumagillin, as an antimicrobial agent, is a potent and selective inhibitor of angiogenesis .

HY-N7700A

Guluronic acid sodium 1 Publications Verification G2013 sodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	VEGFR Toll-like Receptor (TLR) COX NO Synthase NF-κB MMP
Guluronic acid (G2013) sodium is an orally active oxidative stress regulator and anti-inflammatory agent that exerts pharmacological effects by down-regulating various pro-inflammatory and oxidative stress-related genes (such as TLR4, NF-κB, iNOS, etc.) and inhibiting the activities of COX-2, MMPs and VEGF. Low-dose Guluronic acid sodium up-regulates the expression of immunoregulatory genes SHIP1 and SOCS1, thereby effectively inhibiting cancer-related inflammation, tumor angiogenesis, cell adhesion and metastasis, while reducing the accumulation of immunosuppressive cells. Guluronic acid sodium significantly prolongs the survival time of tumor-bearing hosts within a concentration range without direct cytotoxicity, demonstrating favorable safety. Guluronic acid sodium has involved in the research of multiple sclerosis, ankylosing spondylitis, breast cancer and other inflammatory diseases .

HY-W015664

2-Methylheptanoic acid	Structural Classification Animals Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Disease Research Fields Source Classification	Fungal
2-Methylheptanoic acid is a naturally occurring branched-chain medium-chain fatty acid with fumigant activity against Aspergillus flavus. 2-Methylheptanoic acid inhibits the growth of Aspergillus flavus and kills its spores via two modes of action, namely fumigation and direct contact, with its fumigant activity being stronger than its direct contact activity. 2-Methylheptanoic acid can be used in studies related to Aspergillus flavus infection .

HY-N0292R

Oleuropein (Standard)	Structural Classification Iridoids Canarium album (Lour.) Rauesch. Terpenoids Phenols Polyphenols Plants Burseraceae Source Classification	Cytochrome P450 Reference Standards PPAR Apoptosis
Oleuropein (Standard) is the analytical standard of Oleuropein. This product is intended for research and analytical applications. Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .

HY-13295R

Vinpocetine (Standard) Ethyl apovincaminate (Standard)	Apocynaceae Alkaloids Piperidine Alkaloids Structural Classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Reference Standards Sodium Channel IKK Phosphodiesterase (PDE)
Vinpocetine (Standard) is the analytical standard of Vinpocetine. This product is intended for research and analytical applications. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na ⁺ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .

HY-N1965

Gaultherin	other families Classification of Application Fields Ketones, Aldehydes, Acids Gaultheria yunnanensis Ericaceae Plants Inflammation/Immunology Disease Research Fields Source Classification	NF-κB p38 MAPK COX Monoamine Oxidase MMP Interleukin Related TNF Receptor Reactive Oxygen Species (ROS)
Gaultherin is an orally active non-steroidal anti-inflammatory agent. Gaultherin selectively inhibits NF-κB, MAPK, COX-2 (IC₅₀ = 0.35 mg/mL), LOX (IC₅₀ = 0.56 mg/mL) and HYAL (IC₅₀ = 28.58 μg/mL) to exert anti-inflammatory, antipyretic and analgesic effects. Gaultherin exhibits modest direct antioxidant capacity, greater in cell-based models. Gaultherin does not affect COX-1 so that avoids the common gastrointestinal side effects of Aspirin (HY-14654) .

HY-N8188

Dehydrojuncusol	Infection other families Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	HCV HCV Protease
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC₅₀=1.35?μM) .

HY-N3931

Gardneramine	Alkaloids Nepenthes mirabilis (Lour.) Druce Plants Nepenthaceae Source Classification	Others
Gardneramine is an orally active alkaloid that acts like papaverine. Gardneramine has peripheral vascular diastolic effect, direct inhibition on myocardium and central inhibition. Gardneramine showed antihypertensive, vasodilatation and atrial inhibition effects in rabbit, dog and guinea pig models, respectively. Gardneramine also inhibits the movement of smooth muscle organs such as the stomach and intestines .

HY-125927

8-Aminoadenosine 1 Publications Verification 8-NH2-Ado	Natural Products Endogenous metabolite Source Classification	DNA/RNA Synthesis Akt mTOR Autophagy Apoptosis
8-Aminoadenosine (8-NH2-Ado), a RNA-directed nucleoside analogue, reduces cellular ATP levels and inhibits mRNA synthesis. 8-Aminoadenosine blocks Akt/mTOR signaling and induces autophagy and apoptosis in a p53-independent manner. 8-Aminoadenosine has antitumor activity .

HY-N6961R

Lapachol (Standard)	Quinones Structural Classification Tabebuia avellanedae Bignoniaceae Plants Naphthalene Quinones	Reference Standards Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite
Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .

HY-N5072R

Desmethylglycitein (Standard) 4',6,7-Trihydroxyisoflavone (Standard)	Structural Classification Flavonoids Leguminosae Glycine max (L.) merr Phenols Polyphenols Plants Isoflavones Source Classification	Reference Standards CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-113224R

Desmosterol (Standard)	Structural Classification Microorganisms Disease markers Endocrine diseases Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite LXR Fatty Acid Synthase (FASN) Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)
Desmosterol (Standard) is the analytical standard of Desmosterol. This product is intended for research and analytical applications. Desmosterol is a cholesterol-like molecule. In the Bloch pathway of cholesterol biosynthesis, Desmosterol is a direct precursor of cholesterol. As an endogenous metabolite, Desmosterol is used to study cholesterol metabolism [1]. Desmosterol is an LXR activator and SREBP inhibitor, which can suppress macrophage inflammasome activation and prevent vascular inflammation and atherosclerosis. A reduction in Desmosterol promotes the production of mitochondrial reactive oxygen species (ROS) in macrophages and pyrin domain-dependent inflammasome activation of NLRP3. Desmosterol holds potential for research in inflammation, metabolism, and cardiovascular diseases [1][2][3].

HY-N14218

Eurystatin A	Microorganisms Antibiotics Other Antibiotics Source Classification	Prolyl Endopeptidase (PREP)
Eurystatin A is a prolyl endopeptidase inhibitor, L-Leucine and L-Ornithine are the direct precursors of the L-Leucine and L-Ornithine moieties of eurystatins A .

HY-N10177

Peniterphenyl A	Infection Microorganisms Classification of Application Fields Phenols Polyphenols Disease Research Fields Source Classification	HSV
Peniterphenyl A is a natural product obtained from a deep-sea-derived Penicillium sp. Peniterphenyl A inhibits HSV-1/2 virus entry into cells and may block HSV-1/2 infection through direct interaction with virus envelope glycoprotein D to interfere with virus adsorption and membrane fusion. Peniterphenyl A is a promising lead compound against HSV-1/2 .

HY-N1965R

Gaultherin (Standard)	Structural Classification other families Ketones, Aldehydes, Acids Gaultheria yunnanensis Ericaceae Plants Source Classification	Reference Standards NF-κB p38 MAPK COX Reactive Oxygen Species (ROS) Monoamine Oxidase MMP Interleukin Related TNF Receptor
Gaultherin (Standard) is the analytical standard for Gaultherin (HY-N1965). Gaultherin is an orally active non-steroidal anti-inflammatory agent. Gaultherin selectively inhibits NF-κB, MAPK, COX-2 (IC₅₀ = 0.35 mg/mL), LOX (IC₅₀ = 0.56 mg/mL) and HYAL (IC₅₀ = 28.58 μg/mL) to exert anti-inflammatory, antipyretic and analgesic effects. Gaultherin exhibits modest direct antioxidant capacity, greater in cell-based models. Gaultherin does not affect COX-1 so that avoids the common gastrointestinal side effects of Aspirin (HY-14654) .

HY-N1942R

5-O-Demethylnobiletin (Standard) 5-Demethylnobiletin (Standard)	Structural Classification Flavonoids Flavones Rutaceae Plants Citrus	Reference Standards Lipoxygenase Leukotriene Receptor
5-O-Demethylnobiletin (Standard) is the analytical standard of 5-O-Demethylnobiletin. This product is intended for research and analytical applications. 5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Citrus jambhiri Lush., is a direct inhibition of 5-LOX (IC₅₀=0.1 μM), without affecting the expression of COX-2. 5-O-Demethylnobiletin (5-Demethylnobiletin) has anti-inflammatory activity, inhibits leukotriene B (4)(LTB4) formation in rat neutrophils and elastase release in human neutrophils with an IC₅₀ of 0.35 μM .

HY-N7368R

Hibifolin (Standard)	Flavonols Structural Classification Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards Adenosine Deaminase Bacterial Caspase
Hibifolin (Standard) is the analytical standard of Hibifolin. This product is intended for research and analytical applications. Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (K_i = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC₅₀ = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .

HY-N0493R

Pectolinarigenin (Standard)	Structural Classification Flavonoids Flavones Campylotropis hirtella (Franch.) Schindl. Phenols Polyphenols Plants Compositae Source Classification	Reference Standards COX Lipoxygenase NF-κB p38 MAPK ERK HIF/HIF Prolyl-Hydroxylase Keap1-Nrf2 PI3K Apoptosis Autophagy
Pectolinarigenin (Standard) is the analytical standard of Pectolinarigenin. This product is intended for research and analytical applications. Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G₂/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma.

HY-N14957

Clavicoronic acid	Natural Products Microorganisms Source Classification	Antibiotic
Clavicoronic acid is an avian myeloblastosis virus and Moloney murine leukemia virus reverse transcriptases inhibitor with K_i values of 130, 68 µM, respectively. Clavicoronic acid inhibits the multiplication of vesicular stomatitis virus by interfering with this virus's RNA-directed RNA-polymerase. Clavicoronic acid shows no cytotoxicity .

HY-W015664R

2-Methylheptanoic acid (Standard)	Structural Classification Animals Ketones, Aldehydes, Acids Source Classification	Reference Standards Fungal
2-Methylheptanoic acid (Standard) is the analytical standard of 2-Methylheptanoic acid (HY-W015664). This product is intended for research and analytical applications. 2-Methylheptanoic acid is a naturally occurring branched-chain medium-chain fatty acid with fumigant activity against Aspergillus flavus. 2-Methylheptanoic acid inhibits the growth of Aspergillus flavus and kills its spores via two modes of action, namely fumigation and direct contact, with its fumigant activity being stronger than its direct contact activity. 2-Methylheptanoic acid can be used in studies related to Aspergillus flavus infection .

HY-118817

Evariquinone	Quinones Structural Classification Microorganisms Anthraquinones Source Classification	Reactive Oxygen Species (ROS) Calcium Channel JNK ERK p38 MAPK Apoptosis
Evariquinone is an anthraquinone compound isolated from the endophytic fungus Colletotrichum sp. JS-0367 of mulberry. Evariquinone possesses direct antioxidant activity. It inhibits excessive phosphorylation of the JNK, ERK1/2 and p38 MAPK signaling pathways by suppressing ROS and Ca ²⁺, thereby reducing neuronal apoptosis. Evariquinone can be used to study glutamate excitotoxicity-related neurological disorders (such as Alzheimer's disease, Parkinson's disease, cerebral ischemia, etc.) .

Cat. No.	Product Name	Chemical Structure

HY-50903S

Rivaroxaban-d4 1 Publications Verification
Rivaroxaban-d₄ (BAY 59-7939-d₄) is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-B0252S1

Hydrochlorothiazid-13C,d2

Hydrochlorothiazid- ¹³C,d₂ is the ¹³C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-10163S

Dabigatran-d4
Dabigatran-d₄ is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S1

Dabigatran-d3
Dabigatran-d₃ is the deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-B0252S

Hydrochlorothiazid-d2

Hydrochlorothiazid-d₂ is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-10163AS

Dabigatran-d4 hydrochloride
Dabigatran-d₄ (hydrochloride) is deuterium labeled Dabigatran, which is a reversible and selective, direct thrombin inhibitor (DTI) with a K_i value of 4.5 nM.

HY-B0252S3

Hydrochlorothiazide-15N2,13C,d2

Hydrochlorothiazide- ¹⁵N₂, ¹³C,d₂ is ¹⁵N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-12177S

Aliskiren-d6 hemifumarate
Aliskiren-d₆ (hemifumarate) is a deuterium labeled Aliskiren hemifumarate. Aliskiren hemifumarate is a direct and orally active renin inhibitor with an IC₅₀ of 1.5 nM .

HY-12176AS

Aliskiren-d6 hydrochloride
Aliskiren-d₆ (hydrochloride) is is deuterium labeled Aliskiren, which is a direct renin inhibitor.

HY-B0375S

Argatroban-d3
Argatroban-d₃ is the deuterium labeled Argatroban. Argatroban (MD-805) is a direct, selective thrombin inhibitor.

HY-B0375S1

Argatroban-13C6 hydrochloride
Argatroban- ¹³C₆ hydrochloride is ¹³C labeled Argatroban (HY-B0375). Argatroban (MD-805) is a direct, selective thrombin inhibitor.

HY-10163S2

Dabigatran-13C6
Dabigatran- ¹³C₆ is the ¹³C labeled Dabigatran . Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-10163S3

Dabigatran-13C,d3
Dabigatran- ¹³C,d₃ is the ¹³C- and deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-136450S

Triclabendazole sulfoxide-d3

Triclabendazole sulfoxide-d₃ is the deuterium labeled Triclabendazole sulfoxide. Triclabendazole sulfoxide (TCBZ-SO) is an orally active ABCG2 inhibitor with antiparasitic activity. Triclabendazole sulfoxide inhibits ABCG2-mediated active efflux and ATPase activity. Triclabendazole sulfoxide increases the intracellular accumulation of Mitoxantrone (HY-13502). Triclabendazole sulfoxide reduces the apical-directed transepithelial transport of Nitrofurantoin and Danofloxacin, while increasing their basolateral-directed transepithelial transport. Triclabendazole sulfoxide elevates the plasma levels of sulfasalazine in wild-type mice. Triclabendazole sulfoxide decreases ABCG2-mediated secretion of Nitrofurantoin into milk in wild-type lactating mice. Triclabendazole sulfoxide can be used in the research of insecticidal agents and cancers such as breast cancer .

HY-136450S1

Triclabendazole sulfoxide-13C,d3

Triclabendazole sulfoxide- ¹³C,d₃ is the ¹³C- and deuterium labeled Triclabendazole sulfoxide. Triclabendazole sulfoxide (TCBZ-SO) is an orally active ABCG2 inhibitor with antiparasitic activity. Triclabendazole sulfoxide inhibits ABCG2-mediated active efflux and ATPase activity. Triclabendazole sulfoxide increases the intracellular accumulation of Mitoxantrone (HY-13502). Triclabendazole sulfoxide reduces the apical-directed transepithelial transport of Nitrofurantoin and Danofloxacin, while increasing their basolateral-directed transepithelial transport. Triclabendazole sulfoxide elevates the plasma levels of sulfasalazine in wild-type mice. Triclabendazole sulfoxide decreases ABCG2-mediated secretion of Nitrofurantoin into milk in wild-type lactating mice. Triclabendazole sulfoxide can be used in the research of insecticidal agents and cancers such as breast cancer .

HY-W705434

Dabigatran etexilate-d11
Dabigatran etexilate-d₁₁ (BIBR 1048-d₁₁) is the deuterium labeled Dabigatran etexilate (HY-10274). Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .

HY-10163S5

Dabigatran-d7
Dabigatran-d₇ (BIBR 953-d₇; BIBR 953ZW-d₇) is the deuterium labeled Dabigatran (HY-10163). Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC₅₀=10 nM) .

HY-13295S

Vinpocetine-d5

Vinpocetine-d₅ is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders .

HY-B0252S2

Hydrochlorothiazide-13C6

Hydrochlorothiazide- ¹³C₆ is the ¹³C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-18660S

Ciraparantag-d8 (tetra(hydrochloride) diacetate)

Ciraparantag-d₈ (PER977-d₈) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .

HY-B1343AS

Pridinol-d5

Pridinol-d₅ is deuterium labeled Pridinol (HY-B1343A) . Pridinol is an orally active, blood-brain permeable, muscarinic acetylcholine receptor (mAChR)-directed muscle relaxant. Pridinol reduces the conduction of impulses to spinal motor neurons and exerts muscle relaxant activity. Pridinol inhibits skeletal muscle contractures in diseases of both central and peripheral origin and can be used in research in the field of musculoskeletal diseases .

HY-W743984

Melagatran-d11

Melagatran-d₁₁ is the deuterium labeled Melagatran (HY-129056). Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia . Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion .

HY-W720629

Cyanamide-15N2

Cyanamide- ¹⁵N2 is the ¹⁵N-labeled Cyanamide (HY-Y0070). Cyanamide is a cell division and plant growth inhibitor, as well as an allelochemical derived from Vicia villosa. Cyanamide inhibits root growth and biomass accumulation in a dose-dependent manner by disrupting the formation of mitotic spindles and phragmoplast complexes, reducing the number of mitotic cells and blocking the cell cycle. The effects of Cyanamide are partially reversible after removal from low-concentration environments. Cyanamide is also a specific inhibitor of aldehyde dehydrogenase (ALDH). Although Cyanamide has no direct effect on tumor growth, it can significantly enhance the anti-tumor efficacy of Cyclophosphamide (HY-17420) at non-toxic doses by inhibiting the inactivation of Cyclophosphamide. Cyanamide enables Cyclophosphamide to exert equivalent therapeutic effects at lower doses, effectively inhibiting the growth of primary and metastatic tumors and prolonging the lifespan of tumor-bearing mice. Cyanamide is commonly used in studies related to ha-1 hepatoma and rls lymphosarcoma .

Cat. No.	Product Name		Classification

HY-115673

LAS17 1 Publications Verification		Alkynes
LAS17 is a potent and selective tyrosine-directed irreversible inhibitor for glutathione S-Transferase Pi (GSTP1) . LAS17 inhibits GSTP1 activity with an IC₅₀ of 0.5 μM . LAS17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-180114

NSS-18		Alkynes
NSS-18 is a potent and reversible inhibitor of AChE and MAO-B, with IC₅₀ values of 1.53 and 1.51 μM respectively. NSS-18 can inhibit the self-aggregation of Aβ. NSS-18 inhibits the intracellular generation of ROS induced by Aβ. NSS-18 shows a moderate neuroprotective effect against 6-OHDA (HY-B1081)-induced neurotoxicity. NSS-18 can form chelates with metal ions such as Cu²⁺, Fe³⁺, and Zn²⁺, with the strongest chelation being with Cu²⁺. NSS-18 can be used for the study of Alzheimer's disease .

Cat. No.	Product Name		Classification

HY-153493A

PF-04523655 sodium		siRNAs siRNA drugs
PF-04523655 sodium is a siRNA directed against RTP801 gene. RTP801 sodium is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.

HY-153493

PF-04523655		siRNAs siRNA drugs
PF-04523655 is a siRNA directed against RTP801 gene. RTP801 is an inhibitor of the mammalian target of rampamycin complex 1 (mTORC1) and downstream transcription factor HIF-1.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Direct Inhibitors

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products